Skip to main content
SpringerLink
Log in

Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin

  • Review Article
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Basal cell carcinoma (BCC) is the most common type of skin cancer, with rising incidence rates primarily attributed to an aging population and ultraviolet radiation exposure. While the majority of BCCs are localized and respond to standard therapies, a very small minority of these tumors become locally destructive or metastasize. These advanced BCCs may not be amenable to localized treatment with surgery and/or radiation therapy. Most BCCs result from mutations in key receptors in the Hedgehog (HH) signaling pathway. As a result, identification of drugs that inhibit the receptor Smoothened (SMO) in the HH pathway has resulted in novel therapeutic approaches to treating patients with advanced BCC. These HH-pathway inhibiting medications have shown efficacy in clinical trials, and two medications, vismodegib and sonidegib, have received FDA approval. However, several limitations of these drugs have been identified, including treatment-limiting adverse events, drug resistance, and the formation of additional malignancies. This paper aims to summarize the clinical trials leading to the approval of SMO inhibitors, as well as reviewing potential mechanisms driving tumor resistance and the formation of cutaneous squamous cell carcinomas. Strategies to overcome some of these challenges, including the development of drugs that inhibit other downstream targets in the HH pathway, are the subject of ongoing clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Asgari M, Moffet H, Ray T, Quesenberry C. Trends in basal cell carcinoma incidence and identification of high-risk subgroups, 1998–2012. JAMA Dermatol. 2015;151(9):976–81.

    Article  PubMed  Google Scholar 

  2. Goldenberg G, Karagiannis T, Palmer J, Lotya J, O’Neill C, Kisa R, et al. Incidence and prevalence of basal cell carcinoma (BCC) and locally advanced BCC (LABCC) in a large commercially insured population in the United States: a retrospective cohort study. J Am Acad Dermatol. 2016;75(5):957–66.

    Article  PubMed  Google Scholar 

  3. Rogers H, Weinstock M, Feldman S, Coldiron B. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US population, 2012. JAMA Dermatol. 2015;151(10):1081–6.

    Article  PubMed  Google Scholar 

  4. Chuang T, Popescu A, Su W, Chute C. Basal cell carcinoma: a population-based incidence study in Rochester, Minnesota. J Am Acad Dermatol. 1990;22(3):413–7.

    Article  CAS  PubMed  Google Scholar 

  5. Andersen L, Davis M. Sex differences in the incidence of skin and skin-related diseases in Olmsted County, Minnesota, United States, and a comparison with other rates published worldwide. Int J Dermatol. 2016;55(9):939–55.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Christenson L, Borrowman T, Vachon C, Tollefson M, Otley C, Weaver A, et al. Incidence of basal and squamous cell carcinomas in a population younger than 40 years. JAMA. 2005;294(6):681–90.

    Article  CAS  PubMed  Google Scholar 

  7. Scrivener Y, Grosshans E, Cribier B. Variations of basal cell carcinomas according to gender, age, location and histopathological subtype. Br J Dermatol. 2002;147:41–7.

    Article  CAS  PubMed  Google Scholar 

  8. Kricker A, Armstrong B, English D, Heenan P. Does intermittent sun exposure cause basal cell carcinoma? a case-control study in Western Australia. Int J Cancer. 1995;60(4):489–94.

    Article  CAS  PubMed  Google Scholar 

  9. Kricker A, Armstrong B, English D, Heenan P. A dose-response curve for sun exposure and basal cell carcinoma. Int J Cancer. 1995;60(4):482–8.

    Article  CAS  PubMed  Google Scholar 

  10. Gallagher R, Hill G, Bajdik C, Fincham S, Coldman A, McLean D, et al. Sunlight exposure, pigmentary factors, and risk of nonmelanocytic skin cancer. I. Basal cell carcinoma. Arch Dermatol. 1995;131(2):157–63.

    Article  CAS  PubMed  Google Scholar 

  11. Karagas M, Stannard V, Mott L, Slattery M, Spencer S, Weinstock M. Use of tanning devices and risk of basal cell and squamous cell skin cancers. J Natl Cancer Inst. 2002;94(3):224–6.

    Article  PubMed  Google Scholar 

  12. Karagas M, Zens M, Li Z, Stukel T, Perry A, Gilbert-Diamond D, et al. Early-onset basal cell carcinoma and indoor tanning: a population-based study. Pediatrics. 2014;134(1):e4–12.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Karagas M, McDonald J, Greenberg E, Stukel T, Weiss J, Baron J, et al. Risk of basal cell and squamous cell skin cancers after ionizing radiation therapy. For The Skin Cancer Prevention Study Group. J Natl Cancer Inst. 1996;88(24):1848–53.

    Article  CAS  PubMed  Google Scholar 

  14. Lichter M, Karagas M, Mott L, Spencer S, Stukel T, Greenberg E. Therapeutic ionizing radiation and the incidence of basal cell carcinoma and squamous cell carcinoma. The New Hampshire Skin Cancer Study Group. Arch Dermatol. 2000;136(8):1007–11.

    Article  CAS  PubMed  Google Scholar 

  15. Cheng P, Weng S, Chiang C, Lai F. Relationship between arsenic-containing drinking water and skin cancers in the arseniasis endemic areas in Taiwan. J Dermatol. 2016;43(2):181–6.

    Article  CAS  PubMed  Google Scholar 

  16. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348(17):1681–91.

    Article  PubMed  Google Scholar 

  17. Tessari G, Girolomoni G. Nonmelanoma skin cancer in solid organ transplant recipients: update on epidemiology, risk factors, and management. Dermatol Surg. 2012;38(10):1622–30.

    Article  CAS  PubMed  Google Scholar 

  18. Castori M, Morrone A, Kanitakis J, Grammatico P. Genetic skin diseases predisposing to basal cell carcinoma. Eur J Dermal. 2012;22(3):299–309.

    Google Scholar 

  19. Hsu M, Liau J, Hong J, Cheng Y, Liao Y, Chen J, et al. Secondary neoplasms arising from nevus sebaceous: a retrospective study of 450 cases in Taiwan. J Dermatol. 2016;43(2):175–80.

    Article  PubMed  Google Scholar 

  20. Kimonis V, Goldstein A, Pastakia B, Yang M, Kase R, DiGiovanna J, et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet. 1997;69(3):299–308.

    Article  CAS  PubMed  Google Scholar 

  21. Gorlin R. Nevoid basal-cell carcinoma syndrome. Medicine. 1987;66(2):98–113.

    Article  CAS  PubMed  Google Scholar 

  22. Lattes R, Kessler R. Metastasizing basal cell epithelioma of the skin; report of two cases. Cancer. 1951;4(4):866–78.

    Article  CAS  PubMed  Google Scholar 

  23. Moser S, Borm J, Mihic-Probst D, Jacobsen C, Kruse Gujer A. Metastatic basal cell carcinoma: report of a case and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;117(2):e79–82.

    Article  PubMed  Google Scholar 

  24. Ingham P, McMahon A. Hedgehog signaling in animal development: paradigms and principles. Genes Dev. 2001;15(23):3059–87.

    Article  CAS  PubMed  Google Scholar 

  25. Hahan H, Wiking C, Zaphiropoulos P, Gailani M, Shanley S, Chidambaram A, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 1996;85:841–51.

    Article  Google Scholar 

  26. Johnson R, Rothman A, Xie J, Goodrich L, Bare J, Bonifas J, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science. 1996;272:1668–71.

    Article  CAS  PubMed  Google Scholar 

  27. Jayaraman S, Rayhan D, Hazany S, Kolodney M. Mutational landscape of basal cell carcinomas by whole-exome sequencing. J Invest Dermatol. 2014;134(1):213–20.

    Article  CAS  PubMed  Google Scholar 

  28. Aszterbaum M, Rothman A, Johnson R, Fisher M, Xie J, Bonifas J, et al. Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with basal cell nevus syndrome. J Invest Dermatol. 1998;110(6):885–8.

    Article  CAS  PubMed  Google Scholar 

  29. Xie J, Murone M, Luoh S, Ryan A, Gu Q, Zhang C, et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature. 1998;391(6662):90–2.

    Article  CAS  PubMed  Google Scholar 

  30. Reifenberger J, Wolter M, Weber R, Megahed M, Ruzicka T, Lichter P, et al. Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res. 1998;58(9):1798–803.

    CAS  PubMed  Google Scholar 

  31. Binns W, James L, Shupe J, Everett G. A congenital cyclopian-type malformation in lambs induced by maternal ingestion of a range plant, veratrum californicum. Am J Vet Res. 1963;24:1164–75.

    CAS  PubMed  Google Scholar 

  32. Chen J, Taipale J, Cooper M, Beachy P. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev. 2002;16(21):2743–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Tremblay M, Nevalainen M, Nair S, Porter J, Castro A, Behnke M, et al. Semisynthetic cyclopamine analogues as potent and orally bioavailable hedgehog pathway antagonists. J Med Chem. 2008;51(21):6646–9.

    Article  CAS  PubMed  Google Scholar 

  34. Wysong A, Aasi S, Tang J. Update on metastatic basal cell carcinoma: a summary of published cases from 1981 through 2011. JAMA Dermatol. 2013;149(5):615–6.

    Article  PubMed  Google Scholar 

  35. Robarge K, Brunton S, Castanedo G, Cui Y, Dina M, Goldsmith R, et al. GDC-0449-A potent inhibitor of the hedgehog pathway. Bioorg Med Chem Lett. 2009;19(19):5576–81.

    Article  CAS  PubMed  Google Scholar 

  36. Von Hoff D, LoRusso P, Rudin C, Reddy J, Yauch R, Tibes R, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009;361(12):1164–72.

    Article  Google Scholar 

  37. LoRusso P, Rudin C, Reddy J, Tibes R, Weiss G, Borad M, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17(8):2502–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92(3):205–16.

    Article  CAS  PubMed  Google Scholar 

  39. LoRusso P, Jimeno A, Dy G, Adjei A, Berlin J, Leichman L, et al. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17(17):5774–82.

    Article  CAS  PubMed  Google Scholar 

  40. Sekulic A, Migden M, Oro A, Dirix L, Lewis K, Hainsworth J, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Sekulic A, Migden M, Lewis K, Hainsworth J, Solomon J, Yoo S, et al. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol. 2015;72:1021–6.

    Article  PubMed  Google Scholar 

  42. Sekulic A, Schadendorf D, Solomon J, Hainsworth J, Lewis K, Dirix L, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (aBCC): a 24-month update of the pivotal ERIVANCE BCC study. J Am Acad Dermatol. 2014;70(5):AB137.

    Google Scholar 

  43. Sekulic A, Migden M, Basset-Seguin N, Garbe C, Gesierich A, Lao C, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: 30-month final update of the pivotal ERIVANCE BCC study. J Am Acad Dermatol. 2015;72(5):AB187.

    Google Scholar 

  44. Sekulic A, Hainsworth J, Lewis K, Oro A, Gesierich A, Mortier L, et al. Vismodegib for advanced basal cell carcinoma: duration of response after vismodegib discontinuation and response to vismodegib retreatment upon disease progression. 2015;72(5):AB195.

    Google Scholar 

  45. Chang A, Solomon J, Hainsworth J, Goldberg L, McDenna E, Day B, et al. Expanded access study of patients with advanced basal cell carcinoma treated with the hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol. 2014;70:60–9.

    Article  CAS  PubMed  Google Scholar 

  46. Basset-Seguin N, Hauschild A, Grob J, Kunstfeld R, Dreno B, Mortier L, et al. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol. 2015;16(6):729–36.

    Article  CAS  PubMed  Google Scholar 

  47. Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: a revised RECIST guideline (version1.1). Eur J Cancer. 2009;45(2):228–47.

    Article  CAS  PubMed  Google Scholar 

  48. Hansson J, Hauschild A, Kunstfeld R, Grob J, Dreno B, Mortier L, et al. Vismodegib, a hedgehog pathway inhibitor, in advanced basal cell carcinoma: STEVIE study primary analysis in 1215 patients. J Clin Oncol. 2016;34:(suppl; abstr 9532).

  49. Tang J, Mackay-Wiggan J, Aszterbaum M, Yauch R, Lindgren J, Chang K, et al. Inhibiting the hedgehog pathway in patients with the Basal-Cell Nevus Syndrome. N Engl J Med. 2012;366(23):2180–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Chang A, Arron S, Migden M, Solomon J, Yoo S, Day B, et al. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials. Orphanet J Rare Dis. 2016;11(1):120.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Sekulic A, MAngold A, Northfelt D, LoRusso P. Advanced basal cell carcinoma of the skin: targeting the hedgehog pathway. Curr Opin Oncol. 2013;25(3):218–223.

  52. Dummer R, Basset-Seguin N, Hansson J, Grob J, Kunstfeld R, Dreno B. Impact of treatment breaks on vismodegib patient outcomes: exploratory analysis of the STEVIE study. J Clin Oncol. 2015;33:(suppl; abstr 9024).

  53. Rogers G, Kunstfeld R, Schadendorf D, Hauschild A, Maher I, Zloty D, et al. Mikie: A randomized, double-blinded, regimen-controlled, phase 2 study to assess the efficacy and safety of two different vismodegib regimens in patients with multiple basal cell carcinomas. J Clin Oncol. 2016;34:(suppl; abstr 9509).

  54. http://www.clinicaltrials.gov identifier NCT01556009. Accessed 11 Dec 2016.

  55. http://www.clinicaltrials.gov identifier NCT02067104. Accessed 11 Dec 2016.

  56. Ally M, Tang J, Lindgren J, Acosta-Raphael M, Rezaee M, Chanana A, et al. Effect of calcium channel blockade on vismodegib-induced muscle cramps. JAMA Dermatol. 2015;151(10):1132–4.

    Article  PubMed  Google Scholar 

  57. Fife K, Herd R, Lalondrelle S, Plummer R, Strong A, Jones S, et al. Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma. Future Oncol. 2016 (Epub ahead of print).

  58. Danial C, Lingala B, Balise R, Oro A, Reddy S, Colevas A, et al. Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma. Br J Dermatol. 2013;169(3):673–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. McCusker M, Basset-Seguin N, Dummer R, Lewis K, Schadendorf D, Sekulic A, et al. Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease. Eur J Cancer. 2014;50(4):774–83.

    Article  PubMed  Google Scholar 

  60. Lewis K, Sekulic A, Hauschild A, Migden M, Oro A, LoRusso P. Vismodegib in the treatment of patients with metastatic basal cell carcinoma and distant metastases: Survival in the pivotal phase II and phase I studies. J Clin Oncol. 2014;32:5s(suppl; abstr 9012).

  61. Ally M, Aasi S, Wysong A, Teng C, Anderson E, Bailey-Healy I, et al. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma. J Am Acad Dermatol. 2014;71:904–11.

    Article  CAS  PubMed  Google Scholar 

  62. Sofen H, Gross K, Goldberg L, Sharata H, Hamilton Egbert B, et al. A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma. J Am Acad Dermatol. 2015;73:99–105.

    Article  CAS  PubMed  Google Scholar 

  63. Alcalay J, Tauber G, Fenig E, Hodak E. Vismodegib as a neoadjuvant treatment to Mohs surgery for aggressive basal cell carcinoma. J Drugs Dermatol. 2015;14(3):219–23.

    PubMed  Google Scholar 

  64. Chang A, Atwood S, Tartar D, Oro A. Surgical excision after neoadjuvant therapy with vismodegib for a locally advanced basal cell carcinoma and resistant basal carcinomas in Gorlin Syndrome. JAMA Dermatol. 2013;149(5):639–41.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Kahana A, Worden F, Elner V. Vismodegib as eye-sparing adjuvant treatment for orbital basal cell carcinoma. JAMA Ophthalmol. 2013;131(10):1364–6.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Ching J, Curtis H, Braue J, Kudchadkar R, Mendoza T, Messina J. The impact of neoadjuvant hedgehog inhibitor therapy on the surgical treatment of extensive basal cell carcinoma. Ann Plast Surg. 2015;74(4):S193–7.

    Article  CAS  PubMed  Google Scholar 

  67. http://www.clinicaltrials.gov identifier NCT01631331. Accessed 11 Dec 2016.

  68. http://www.clinicaltrials.gov identifier NCT02667574. Accessed 11 Dec 2016.

  69. http://www.clinicaltrials.gov identifier NCT01898598. Accessed 11 Dec 2016.

  70. http://www.clinicaltrials.gov identifier NCT02956889. Accessed 11 Dec 2016.

  71. http://www.clinicaltrials.gov identifier NCT01835626. Accessed 11 Dec 2016.

  72. Rodon J, Tawbi H, Thomas A, Stoller R, Turtschi C, Baselga J, et al. A Phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res. 2014;20(7):1900–9.

    Article  CAS  PubMed  Google Scholar 

  73. Migden M, Guminski A, Gutzmer R, Dirix L, Lewis K, Combemale P, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomized, double-blind phase 2 trial. Lancet Oncol. 2015;16:716–28.

    Article  CAS  PubMed  Google Scholar 

  74. Dummer R, Migden M, Guminski A, Gutzmer R, Kudchadkar R, Lewis K, et al. Efficacy and safety of sonidegib in patients with locally advanced or metastatic basal cell carcinoma: BOLT 30-month analysis. J Clin Oncol. 2016;34:(suppl; abstr 9538).

  75. http://www.clinicaltrials.gov identifier NCT01350115. Accessed 11 Dec 2016.

  76. Skvara H, Kalthoff F, Meingassner J, Wolff-Winiski B, Aschauer H, Kelleher J, et al. Topical treatment of basal cell carcinomas in nevoid basal cell carcinoma syndrome with a smoothened inhibitor. J Invest Dermatol. 2011;131(8):1735–44.

    Article  CAS  PubMed  Google Scholar 

  77. Siu L, Papadopoulos K, Alberts S, Kirchoff-Ross R, Bakkalagadda B, Lang L, et al. A first-in-human, phase I study of an oral hedgehog pathway antagonist, BMS-833923, in subjects with advanced or metastatic solid tumors. J Clin Oncol. 2010;28(15s):(suppl; abstr 2501).

  78. Bendell J, Weiss G, Infante J, Ramanathan R, Jones S, Korn R, et al. A phase I dose-escalation, pharmacokinetic and pharmacodynamic evaluation of LY2940680, an oral Smo inhibitor. Eur J Cancer. 2012;48(6):182.

    Article  Google Scholar 

  79. Wagner A, Messersmith W, Shaik M, Li S, Zheng X, McLachlan K, et al. A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2015;21(5):1044–51.

    Article  CAS  PubMed  Google Scholar 

  80. Peukert S, He F, Dai M, Zhang R, Sun Y, Miller-Moslin K, et al. Discovery of NVP-LEQ506, a second-generation inhibitor of smoothened. Chem Med Chem. 2013;8(8):1261–5.

    Article  CAS  PubMed  Google Scholar 

  81. Kim J, Tang J, Gong R, Kim J, Lee J, Clemons K, et al. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell. 2010;17(4):388–99.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Kim J, Lee J, Kim J, Gardner D, Beachy P. Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc Natl Acad Sci USA. 2010;107(30):13432–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Kim J, Aftab B, Tang J, Kim D, Lee A, Rezaee M, et al. Itraconazole and arsenic trioxide inhibit hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell. 2013;23(1):23–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Kim D, Kim J, Spaunhurst K, Montoya J, Khodosh R, Chandra K, et al. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol. 2014;32(8):745–51.

    Article  CAS  PubMed  Google Scholar 

  85. http://www.clinicaltrials.gov identifier NCT02354261. Accessed 11 Dec 2016.

  86. http://www.clinicaltrials.gov identifier NCT02120677. Accessed 11 Dec 2016.

  87. http://www.clinicaltrials.gov identifier NCT02735356. Accessed 11 Dec 2016.

  88. Chen B, Trang V, Lee A, Williams N, Wilson A, Epstein E, et al. Posaconazole, a second-generation triazole antifungal drug, inhibits the hedgehog signaling pathway and progression of basal cell carcinoma. Mol Cancer Ther. 2016;15(5):866–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Iarrobino A, Messina J, Kudchadkar R, Sondak V. Emergence of a squamous cell carcinoma phenotype following treatment of metastatic basal cell carcinoma with vismodegib. J Am Acad Dermatol. 2013;69(1):e33–4.

    Article  PubMed  Google Scholar 

  90. Aasi S, Silkiss R, Tang J, Wysong A, Liu A, Epstein E, et al. New onset keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases. JAMA Dermatol. 2013;149(2):242–3.

    Article  PubMed  PubMed Central  Google Scholar 

  91. Orouji A, Goerdt S, Utikal J, Leverkus M. Multiple highly and moderately differentiated squamous cell carcinomas of the skin during vismodegib treatment of inoperable basal cell carcinoma. Br J Dermatol. 2014;171(2):431–3.

    Article  CAS  PubMed  Google Scholar 

  92. Zhu G, Sundram U, Chang A. Two different scenarios of squamous cell carcinoma within advanced basal cell carcinomas: cases illustrating the importance of serial biopsy during vismodegib usage. JAMA Dermatol. 2014;150(9):970–3.

    Article  PubMed  Google Scholar 

  93. Saintes C, Saint-Jean M, Brocard A, Peuvrel L, Renaut J, Khammari A, et al. Development of squamous cell carcinoma into basal cell carcinoma under treatment with vismodegib. J Eur Acad Dermatol Venereol. 2015;29(5):1006–9.

    Article  CAS  PubMed  Google Scholar 

  94. Poulalhon N, Dalle S, Balme B, Thomas L. Fast-growing cutaneous squamous cell carcinoma in a patient treated with vismodegib. Dermatology. 2015;230(2):101–4.

    Article  PubMed  Google Scholar 

  95. Zhao X, Ponomaryov T, Ornell K, Zhou P, Dabral S, Pak E, et al. RAS/MAPK activation drives resistance to SMO inhibition, metastasis, and tumor evolution in SHH pathway-dependent tumors. Cancer Res. 2015;75(17):3623–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Ransohoff K, Tang J, Sarin K. Squamous change in basal-cell carcinoma with drug resistance. N Engl J Med. 2015;373(11):1079–82.

    Article  CAS  PubMed  Google Scholar 

  97. Yauch R, Dijkgraaf G, Alicke B, Januario T, Ahn C, Holcomb T, et al. Smoothened mutation confers resistance to a hedgehog pathway inhibitor in medulloblastoma. Science. 2009;326:572–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Chang A, Oro A. Initial assessment of tumor regrowth after vismodegib in advanced basal cell carcinoma. Arch Dermatol. 2012;148(11):1324–5.

    Article  PubMed  PubMed Central  Google Scholar 

  99. Zhu G, Li A, Chang A. Patient with Gorlin syndrome and metastatic basal cell carcinoma refractory to smoothened inhibitors. JAMA Dermatol. 2014;150(8):877–9.

    Article  PubMed  Google Scholar 

  100. Meani R, Lim S, Chang A, Kelly J. Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449). Australas J Dermatol. 2014;55(3):218–21.

    Article  PubMed  Google Scholar 

  101. Brinkhuizen T, Reinders M, van Geel M, Hendriksen A, Paulussen A, Winnepenninckx V, et al. Acquired resistance to the hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma. J Am Acad Dermatol. 2014;71(5):1005–8.

    Article  CAS  PubMed  Google Scholar 

  102. Pricl S, Cortelazzi B, Dal Col V, Marson D, Laurini E, Fermeglia M, et al. Smoothened receptor mutations dictate resistance to vismodegib in basal cell carcinoma. Mol Oncol. 2015;9(2):389–97.

    Article  CAS  PubMed  Google Scholar 

  103. Buonamici S, Williams J, Morrissey M, Wang A, Guo R, Vattay A, et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3 K pathway in medulloblastoma. Sci Transl Med. 2010;2(51):51–70.

    Article  Google Scholar 

  104. Dijkgraaf G, Alicke B, Weinmann L, Januario T, West K, Modrusan Z, et al. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res. 2011;71(2):435–44.

    Article  CAS  PubMed  Google Scholar 

  105. Sharpe H, Pau G, Dijkgraaf G, Basset-Seguin N, Modrusan Z, Januario T, et al. Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell. 2015;27(3):327–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Atwood S, Sarin K, Whitson R, Li J, Kim G, Rezaee M, et al. Smoothened variants explain the majority of drug resistance in basal cell carcinoma. Cancer Cell. 2015;27(3):342–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Ally M, Ransohoff K, Sarin K, Atwood S, Rezaee M, Bailey-Healy I, et al. Effects of combined treatment with arsenic trioxide and itraconazole in patients with refractory metastatic basal cell carcinoma. JAMA Dermatol. 2016;152(4):452–6.

    Article  PubMed  PubMed Central  Google Scholar 

  108. Lipson E, Lilo M, Ogurtsova A, Esandrio J, Xu H, Brothers P, et al. Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade. J Immunother Cancer. 2017;5:23.

    Article  PubMed  PubMed Central  Google Scholar 

  109. http://www.clinicaltrials.gov identifier NCT02690948. Accessed 2 Dec 2017.

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Mayo Clinic College of Medicine and Science, Onalaska, WI, USA

    Rebecca Danhof

  2. Division of Hematology and Oncology, Department of Internal Medicine, University of Colorado School of Medicine, Aurora, CO, USA

    Karl Lewis

  3. Department of Dermatology, University of Colorado School of Medicine, Mail Stop F703, 1665, North Aurora Court, Aurora, CO, 80045, USA

    Mariah Brown

Authors
  1. Rebecca Danhof
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karl Lewis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mariah Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mariah Brown.

Ethics declarations

Funding

None.

Conflicts of interest

Karl Lewis has received research grants from Roche/Genentech and Novartis, and consulting fees or honorarium from Roche/Genentech and SunPharma. Rebecca Danhof and Mariah Brown declare no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Danhof, R., Lewis, K. & Brown, M. Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin. Am J Clin Dermatol 19, 195–207 (2018). https://doi.org/10.1007/s40257-017-0319-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40257-017-0319-4

Search

Navigation